L

Lineage Cell Therapeutics Inc
TASE:LCTX

Watchlist Manager
Lineage Cell Therapeutics Inc
TASE:LCTX
Watchlist
Price: 361.6 ILS 1.43% Market Closed
Market Cap: 181.9m ILS

Intrinsic Value

LCTX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one LCTX stock under the Base Case scenario is 990.26 ILS. Compared to the current market price of 361.6 ILS, Lineage Cell Therapeutics Inc is Undervalued by 63%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

LCTX Intrinsic Value
990.26 ILS
Undervaluation 63%
Intrinsic Value
Price
L
Worst Case
Base Case
Best Case

Valuation History
Lineage Cell Therapeutics Inc

Valuation History Unavailable

Historical valuation for LCTX cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%
Compare LCTX to

Fundamental Analysis

Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about LCTX?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Lineage Cell Therapeutics Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Lineage Cell Therapeutics Inc

Current Assets 50m
Cash & Short-Term Investments 47.9m
Receivables 213k
Other Current Assets 1.9m
Non-Current Assets 61.8m
PP&E 4.1m
Intangibles 57.2m
Other Non-Current Assets 504k
Efficiency

Free Cash Flow Analysis
Lineage Cell Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Lineage Cell Therapeutics Inc

Revenue
9.6m USD
Cost of Revenue
-272k USD
Gross Profit
9.3m USD
Operating Expenses
-30.6m USD
Operating Income
-21.3m USD
Other Expenses
5.1m USD
Net Income
-16.2m USD
Fundamental Scores

LCTX Profitability Score
Profitability Due Diligence

Lineage Cell Therapeutics Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
ROE is Increasing
ROIC is Increasing
32/100
Profitability
Score

Lineage Cell Therapeutics Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

LCTX Solvency Score
Solvency Due Diligence

Lineage Cell Therapeutics Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Short-Term Solvency
Long-Term Solvency
54/100
Solvency
Score

Lineage Cell Therapeutics Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

LCTX Price Targets Summary
Lineage Cell Therapeutics Inc

Wall Street analysts forecast LCTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LCTX is 1 300.97 ILS with a low forecast of 493.36 ILS and a high forecast of 3 077.37 ILS.

Lowest
Price Target
493.36 ILS
36% Upside
Average
Price Target
1 300.97 ILS
260% Upside
Highest
Price Target
3 077.37 ILS
751% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Lineage Cell Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for LCTX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

LCTX Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one LCTX stock?

The intrinsic value of one LCTX stock under the Base Case scenario is 990.26 ILS.

Is LCTX stock undervalued or overvalued?

Compared to the current market price of 361.6 ILS, Lineage Cell Therapeutics Inc is Undervalued by 63%.

Back to Top